Shopping Cart 0
Cart Subtotal
USD 0

Pfizer Inc (PFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, immune disorders and rare diseases, besides vaccines. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells prescription medicines through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It sells consumer healthcare products through pharmacies, retail chains, distributors and grocery and convenience stores. The company provides its products in the North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

Pfizer Inc (PFE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 13

List of Figures 19

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25

Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26

Pfizer Inc, Pharmaceuticals & Healthcare, Deal Details 50

Asset Purchase 50

Pfizer to Acquire Neksium Brand from AstraZeneca 50

Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 51

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 53

Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 54

Medivation Acquires Rights to Talazoparib from BioMarin Pharma 55

Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 56

Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 57

Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 58

Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 60

Pfizer Acquires Melanocortin Receptors from MRC Technology 62

Pfizer Plans To Sell Certain Ohthalmology R&D Assets 63

Pfizer Completes Acquisition Of Polocard From Polpharma For USD 32 Million 64

Venture Financing 65

Morphic Therapeutic Raises USD80 Million in Series B Financing 65

Biodesy Raises USD20 Million in Series C Venture Financing 67

4D Molecular Therapeutics Raises USD90 Million in Series B Venture Financing 68

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 70

Therachon Raises USD60 Million in Mezzanine Financing 72

Nimbus Therapeutics Raises USD65 Million in Financing 74

Cortexyme Raises USD76 Million in Series B Venture Financing 76

Strata Oncology Raises USD26 Million in Series B Venture Financing 78

Allogene Therapeutics to Raise USD300 Million in Series A Financing 80

Adapsyn Bioscience Raises Funds through Venture Financing 82

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 83

Cydan Raises USD34 Million in Venture Financing 85

Palleon Pharma Raises USD47.6 Million in Series A Financing 86

SpringWorks Therapeutics Raises USD103 Million in Series A Financing 87

Complexa Raises USD62 Million in Series C Financing 89

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 90

Neuronetics Raises USD15 Million in Series G Round of Financing 92

Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 94

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 96

Circle Pharma Raises Funds through Series A Preferred Stock Financing 98

Ixchelsis Raises Additional USD12 Million in Venture Financing 99

Vtesse Raises USD17 Million in Extended Series A Financing 100

Second Genome Raises USD8.4 Million in Extended Series B Financing 101

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 102

Storm Therapeutics Raises USD16 Million in Series A Venture Financing 104

Blade Therapeutics Raises USD27 Million in Series B Financing 105

Second Genome Raises USD42.6 Million in Series B Financing 107

Cydan Development Raises USD31 Million in Series A Financing 109

Metabomed Raises USD18 Million in Series A Venture Financing 110

Mission Therapeutics Raises USD85.7 Million in Financing Round 111

Biodesy Raises USD10 Million in Series B Financing 112

Lodo Therapeutics Raises USD17 Million in Series A Financing 113

Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 115

NextCure Raises USD67 Million in Series A Financing 116

Petra Pharma Raises USD48 Million in Series A Financing 118

Cortexyme Raises USD15 Million in Series A Financing Round 120

Merus Raises USD46.4 Million in First Tranche of Series C Financing 121

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 123

Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 125

Mirna Therapeutics Raises USD41.8 Million in Series D Financing 126

Nimbus Therapeutics Raises USD43 Million in Series B Financing 128

Mersana Therapeutics Raises USD35 Million in Series B Financing 130

Vtesse Raises USD25 Million in Series A Financing 131

CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 132

Ziarco Raises USD33 Million in Series B Venture Financing 133

Quartet Medicine Raises USD17 Million in Series A Venture Financing 134

Circle Pharma Raises Funds through Seed Financing 135

Epic Sciences Raises USD30 Million in Series C Venture Financing 136

NexImmune Raises USD3 Million in Venture Financing 137

Mission Therapeutics Raises USD 32 Million In Series B Financing 138

Biodesy Raises USD 15 Million In Series A Financing 139

Merus Raises USD 42 Million In Extended Series B Financing 140

Cydan Raises USD 26 Million In Venture Financing 142

Esperion Therapeutics Raises USD 33 Million In Venture Financing 144

Aquinox Pharma Raises USD 18 Million In Series C Financing 146

Esperion Therapeutics Raises USD 1 Million In Venture Financing 147

Flexion Therapeutics Raises USD20 Million In Series B Financing 148

Rhythm Pharma Raises USD 33 Million In Series B Financing 149

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 151

Epic Sciences Raises USD 13 Million In Series B Financing 153

Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 154

Mirna Therapeutics Raises USD 34 Million In Series C Financing 155

Mersana Therapeutics Raises USD 27 Million In Series A-1 Financing 157

InnoPharma Raises USD 8 Million In Venture Financing 159

Flexion Therapeutics Raises Additional USD 13 Million In Series A Financing 160

Celladon Raises Additional USD 10 Million In Series D Financing 161

Private Equity 163

Bain Capital May Acquire Laboratorio Teuto Brasileiro 163

Partnerships 164

Pfizer Enters into Licensing Agreement with Scripps Research Institute 164

Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 165

Nektar Therapeutics Enters into Collaboration Agreement with Pfizer 166

Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 167

Pfizer Enters into Co-Development Agreement with Novartis 168

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 169

Bain Capital and Pfizer Form Joint Venture 170

Myriad Genetics and Pfizer Enter into Agreement 171

Calithera Biosciences Enters into Partnership with Pfizer 172

Atomwise Enters into Evaluation Agreement with Pfizer 173

CYTOO Enters into Research and Option Agreement with Pfizer 174

Checkmate Pharma Enters into Partnership with Merck and Pfizer 175

BioNTech Enters into R&D Agreement with Pfizer 176

Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 177

Vyriad Enters into Collaboration Agreement with Merck and Pfizer 178

XtalPi Enters into Research Agreement with Pfizer 179

BioDuro Enters into Agreement with Pfizer 180

Neofluidics Enters into Agreement with Pfizer 181

NetVation DL Medicine Enters into Research Agreement with Pfizer 182

MindImmune Therapeutics Enters into Research Agreement with Pfizer 183

Kite Pharma Enters into Partnership with Pfizer 184

Adapsyn Bioscience Enters into Research Agreement with Pfizer 185

Array BioPharma Enters into Agreement with Pfizer 186

Encycle Therapeutics Enters into Research Agreement with Pfizer 187

Themis Medicare Forms Joint Venture Agreement with Global Pharmatech 188

University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 189

Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 190

Alcyone Lifesciences Enters into Agreement with Pfizer 191

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 192

Astellas Pharma Amends Agreement with Pfizer 193

EpiThany Enters into Agreement with Merck and Pfizer 194

VAXIMM Enters into Agreement with Merck and Pfizer 195

Domain Therapeutics Enters into Partnership with Pfizer 196

Pfizer Enters into Agreement with Washington University in St. Louis 197

Edelris Enters into Research Agreement with Pfizer 198

AbCellera Biologics Enters into Research Agreement with Pfizer 199

Pfizer Partners with NovaMedica 200

PegBio Partners with Pfizer 201

Pfizer Enters into Agreement with National Cancer Institute 202

Debiopharm Partners with Merck and Pfizer 203

Transgene Enters into Agreement with Merck and Pfizer 204

Circle Pharma Partners with Pfizer 205

Pfizer and CR Saike Pharma Enter into Distribution Agreement 206

Pfizer Partners with inVentiv Health 207

Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 208

BioRap Technologies Enters into Co- Development Agreement with Pfizer 209

Pfizer Enters into Agreement with NovaQuest Capital Management 210

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 211

Merck, Pfizer and Verastem Enter into Agreement 212

Pfizer Enters into Partnership Agreement with RPI Finance Trust 213

Pfizer Enters into Agreement with California Institute for Biomedical Research 214

Pfizer Enters into Research Agreement with Adaptive Biotech 215

Merck, Pfizer and Syndax Pharma Enter into Agreement 216

Heptares Therapeutics Enters into Agreement with Pfizer 217

Pfizer Enters into Agreement with Biovac Institute 218

Pfizer Enters into Agreement with GlaxoSmithKline 219

Pfizer Enters into Agreement with Synthon 220

Centers for Therapeutic Innovation Enters into Research Agreement with Jeffrey Modell Foundation 221

CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 222

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 223

Regimmune Enters into Research Agreement with JDRF and Pfizer 224

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 225

HiFiBiO Enters into Research Agreement with Pfizer 226

Pharmacosmos Enters into Agreement with Pfizer 227

Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 228

University of Dundee Enters into Research Agreement with Pfizer 229

HemoShear Enters into Agreement with Pfizer 230

Pfizer Enters into Co-Development Agreement with Merck 231

Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 233

Crohns & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 234

Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 235

X-Chem Enters into Co-Development Agreement with Pfizer 237

KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 238

Cambridge University, Imperial College London, Kings College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 239

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 241

BioRestorative Therapies Enters into Research Agreement with Pfizer 242

Process Systems Enters Into Co-Development Agreement With Pfizer 243

Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 244

Octapharma Enters Into Co-Marketing Agreement With Pfizer 245

Protagen Enters Into Biomarker Discovery Agreement With Pfizer 246

Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 247

Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 248

Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 249

Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 250

Centers For Therapeutic Innovation Partners with UC San Francisco 251

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 252

Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 253

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 254

OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 255

Humedica Enters Into Agreement With Pfizer 257

AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 258

Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 259

Apredica Enters Into Research Agreement With Pfizer 260

Mochida Pharma Enters Into Agreement With Hospira Japan To Distribute And Promote Oncology Products 261

Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 262

Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 263

SFJ Pharma Enters Into Co-Development Agreement With Pfizer For Dacomitinib 264

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 265

Nodality Enters Into Agreement With Pfizer For Single Cell Network Profiling Technology 266

Pfizer Enters Into Co-Development Agreement With Harvard University 267

Cold Spring Harbor Labs Enters Into Research Agreement With Pfizer For New Cancer Therapies 268

Ildong Pharma Enters Into Co-Promotion Agreement With Pfizer Pharma For Generic Drugs 269

Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 270

Pfizer Enters into Co-Promotion Agreement with Specpharm 271

Pfizer Plans To Enter Into Co-Development Agreement With India-Based Pharma Company 272

Pfizer Enters Into Co-Marketing Agreement With Biologics For Inlyta 273

KineMed Extends Research Agreement With Pfizer 274

ICM Enters into Research Collaboration with Pfizer 275

KineMed Enters Into Co-Development Agreement With Pfizer 276

SFJ Pharma Enters Into Co-Development Agreement With Pfizer 277

Licensing Agreements 278

Pfizer Enters into Licensing Agreement with Cancer Therapeutics CRC 278

Pfizer Amends Licensing Agreement with Spark Therapeutics 279

Allogene Therapeutics Enters into Licensing Agreement with Pfizer 281

Suzhou Kintor Pharma Enters into Licensing Agreement with Pfizer 282

Imcyse Research Agreement with Pfizer 283

Pfizer Enters into Licensing Agreement with Distributed Bio for SuperHuman Platform 284

Pfizer Enters into Licensing Agreement with Berkeley Lights 285

Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 286

Pfizer Enters into Licensing Agreement with Arvinas 287

SpringWorks Therapeutics Receives Rights from Pfizer 288

Pfizer Amends Licensing Agreement with Basilea Pharma 289

Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 290

Pfizer Enters into Licensing Agreement with HitGen 291

Absorption Systems Enters into Licensing Agreement with Pfizer 292

Pfizer Enters into Licensing Agreement with BioInvent International 293

Pfizer Enters into Licensing Agreement with Ab Initio Biotherapeutics 294

Pfizer Enters into Licensing Agreement with OncoImmune 295

Pfizer Enters into Option Agreement with AnTolRx 296

Pfizer Enters into Licensing Agreement with Western Oncolytics 297

Shire Enters into Licensing Agreement with Pfizer 298

Pfizer Inc - Key Competitors 499

Pfizer Inc - Key Employees 500

Pfizer Inc - Locations And Subsidiaries 502

Head Office 502

Other Locations & Subsidiaries 502

Joint Venture 525

Recent Developments 526

Strategy And Business Planning 526

Oct 30, 2018: Novartis and Pfizer partner to advance NASH therapy 526

Oct 24, 2018: Pfizer partners with Bain Capital to launch new CNS therapy firm 527

Jul 24, 2018: Pfizer to build $465m injectable medicines facility in US 528

Jul 11, 2018: Pfizer to split into three businesses 529

Jan 04, 2018: Jacobs Appointed as EPCM Contractor for New Gene Therapy Manufacturing Facility 530

Oct 10, 2017: Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business 531

Aug 07, 2017: Pfizer to Invest in Gene Therapy Manufacturing Facility in North Carolina 532

Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 534

Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri 535

Mar 06, 2017: Pfizer Selects Turner & Townsend For Expansion Of Its Clinical Research Unit In Belgium 536

Financial Announcements 537

Jul 31, 2018: Pfizer reports second-quarter 2018 results 537

May 01, 2018: Pfizer Reports First-Quarter 2018 Results 542

Jan 30, 2018: Pfizer Reports Fourth-Quarter And Full-Year 2017 Results 546

Oct 31, 2017: Pfizer Reports Third-Quarter 2017 Results 553

Oct 30, 2017: Pfizer reports thirdquarter 2018 results 556

Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results 565

May 02, 2017: Pfizer Reports First-Quarter 2017 Results 569

Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results 573

Corporate Communications 578

Oct 09, 2018: Pfizer announces Executive Leadership Team 578

Oct 01, 2018: Pfizer announces CEO succession 579

Sep 18, 2018: Good Health and Well-Being : A Mission for Business and Society 581

Jun 12, 2018: Extending Antibiotic Donations to Eliminate Trachoma 582

Mar 05, 2018: Pfizer Names Dan R. Littman As Board Director 583

Feb 23, 2018: Pfizer Appoints Albert Bourla As Board Director 584

Jan 08, 2018: Pfizer Ends Alzheimer's and Parkinson's Disease Programs, to Eliminate 300 Jobs 585

Nov 13, 2017: Pfizer Names Albert Bourla Chief Operating Officer 586

Oct 04, 2017: AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics Join Walgreens to Combat Prescription Drug Abuse by Expanding Safe Medication Disposal Program 588

Feb 23, 2017: Ronald E. Blaylock Elected to Pfizers Board of Directors 590

Legal and Regulatory 591

Jun 11, 2018: Pfizer wins appeal against CMA fine over epilepsy drug price 591

May 24, 2018: Drug Maker Pfizer Agrees to Pay $23.85 Million to Resolve False Claims Act Liability for Paying Kickbacks 592

Government and Public Interest 594

Oct 04, 2018: Pfizer to award more than 3 million in grants to further breast cancer research 594

Sep 04, 2018: Pfizer estimates $100M in supply chain costs for adapting to Brexit requirements 595

Jul 11, 2018: Pfizer reverses drug price hike after President Trumps protests 596

Jun 08, 2018: GEA supports Pfizer to change from batch-based to continuous manufacturing 597

May 30, 2018: The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families 598

Feb 02, 2018: BCRF Announces Expansion of the Drug Research Collaborative 599

Nov 20, 2017: NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care 600

Nov 16, 2017: Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance 601


List Of Figure

List of Figures

Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25


List Of Table

List of Tables

Pfizer Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Pfizer Inc, Deals By Therapy Area, 2012 to YTD 2018 23

Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25

Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26

Pfizer to Acquire Neksium Brand from AstraZeneca 50

Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 51

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 53

Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 54

Medivation Acquires Rights to Talazoparib from BioMarin Pharma 55

Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 56

Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 57

Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 58

Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 60

Pfizer Acquires Melanocortin Receptors from MRC Technology 62

Pfizer Plans To Sell Certain Ohthalmology R&D Assets 63

Pfizer Completes Acquisition Of Polocard From Polpharma For USD 32 Million 64

Morphic Therapeutic Raises USD80 Million in Series B Financing 65

Biodesy Raises USD20 Million in Series C Venture Financing 67

4D Molecular Therapeutics Raises USD90 Million in Series B Venture Financing 68

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 70

Therachon Raises USD60 Million in Mezzanine Financing 72

Nimbus Therapeutics Raises USD65 Million in Financing 74

Cortexyme Raises USD76 Million in Series B Venture Financing 76

Strata Oncology Raises USD26 Million in Series B Venture Financing 78

Allogene Therapeutics to Raise USD300 Million in Series A Financing 80

Adapsyn Bioscience Raises Funds through Venture Financing 82

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 83

Cydan Raises USD34 Million in Venture Financing 85

Palleon Pharma Raises USD47.6 Million in Series A Financing 86

SpringWorks Therapeutics Raises USD103 Million in Series A Financing 87

Complexa Raises USD62 Million in Series C Financing 89

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 90

Neuronetics Raises USD15 Million in Series G Round of Financing 92

Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 94

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 96

Circle Pharma Raises Funds through Series A Preferred Stock Financing 98

Ixchelsis Raises Additional USD12 Million in Venture Financing 99

Vtesse Raises USD17 Million in Extended Series A Financing 100

Second Genome Raises USD8.4 Million in Extended Series B Financing 101

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 102

Storm Therapeutics Raises USD16 Million in Series A Venture Financing 104

Blade Therapeutics Raises USD27 Million in Series B Financing 105

Second Genome Raises USD42.6 Million in Series B Financing 107

Cydan Development Raises USD31 Million in Series A Financing 109

Metabomed Raises USD18 Million in Series A Venture Financing 110

Mission Therapeutics Raises USD85.7 Million in Financing Round 111

Biodesy Raises USD10 Million in Series B Financing 112

Lodo Therapeutics Raises USD17 Million in Series A Financing 113

Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 115

NextCure Raises USD67 Million in Series A Financing 116

Petra Pharma Raises USD48 Million in Series A Financing 118

Cortexyme Raises USD15 Million in Series A Financing Round 120

Merus Raises USD46.4 Million in First Tranche of Series C Financing 121

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 123

Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 125

Mirna Therapeutics Raises USD41.8 Million in Series D Financing 126

Nimbus Therapeutics Raises USD43 Million in Series B Financing 128

Mersana Therapeutics Raises USD35 Million in Series B Financing 130

Vtesse Raises USD25 Million in Series A Financing 131

CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 132

Ziarco Raises USD33 Million in Series B Venture Financing 133

Quartet Medicine Raises USD17 Million in Series A Venture Financing 134

Circle Pharma Raises Funds through Seed Financing 135

Epic Sciences Raises USD30 Million in Series C Venture Financing 136

NexImmune Raises USD3 Million in Venture Financing 137

Mission Therapeutics Raises USD 32 Million In Series B Financing 138

Biodesy Raises USD 15 Million In Series A Financing 139

Merus Raises USD 42 Million In Extended Series B Financing 140

Cydan Raises USD 26 Million In Venture Financing 142

Esperion Therapeutics Raises USD 33 Million In Venture Financing 144

Aquinox Pharma Raises USD 18 Million In Series C Financing 146

Esperion Therapeutics Raises USD 1 Million In Venture Financing 147

Flexion Therapeutics Raises USD20 Million In Series B Financing 148

Rhythm Pharma Raises USD 33 Million In Series B Financing 149

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 151

Epic Sciences Raises USD 13 Million In Series B Financing 153

Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 154

Mirna Therapeutics Raises USD 34 Million In Series C Financing 155

Mersana Therapeutics Raises USD 27 Million In Series A-1 Financing 157

InnoPharma Raises USD 8 Million In Venture Financing 159

Flexion Therapeutics Raises Additional USD 13 Million In Series A Financing 160

Celladon Raises Additional USD 10 Million In Series D Financing 161

Bain Capital May Acquire Laboratorio Teuto Brasileiro 163

Pfizer Enters into Licensing Agreement with Scripps Research Institute 164

Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 165

Nektar Therapeutics Enters into Collaboration Agreement with Pfizer 166

Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 167

Pfizer Enters into Co-Development Agreement with Novartis 168

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 169

Bain Capital and Pfizer Form Joint Venture 170

Myriad Genetics and Pfizer Enter into Agreement 171

Calithera Biosciences Enters into Partnership with Pfizer 172

Atomwise Enters into Evaluation Agreement with Pfizer 173

CYTOO Enters into Research and Option Agreement with Pfizer 174

Checkmate Pharma Enters into Partnership with Merck and Pfizer 175

BioNTech Enters into R&D Agreement with Pfizer 176

Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 177

Vyriad Enters into Collaboration Agreement with Merck and Pfizer 178

XtalPi Enters into Research Agreement with Pfizer 179

BioDuro Enters into Agreement with Pfizer 180

Neofluidics Enters into Agreement with Pfizer 181

NetVation DL Medicine Enters into Research Agreement with Pfizer 182

MindImmune Therapeutics Enters into Research Agreement with Pfizer 183

Kite Pharma Enters into Partnership with Pfizer 184

Adapsyn Bioscience Enters into Research Agreement with Pfizer 185

Array BioPharma Enters into Agreement with Pfizer 186

Encycle Therapeutics Enters into Research Agreement with Pfizer 187

Themis Medicare Forms Joint Venture Agreement with Global Pharmatech 188

University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 189

Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 190

Alcyone Lifesciences Enters into Agreement with Pfizer 191

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 192

Astellas Pharma Amends Agreement with Pfizer 193

EpiThany Enters into Agreement with Merck and Pfizer 194

VAXIMM Enters into Agreement with Merck and Pfizer 195

Domain Therapeutics Enters into Partnership with Pfizer 196

Pfizer Enters into Agreement with Washington University in St. Louis 197

Edelris Enters into Research Agreement with Pfizer 198

AbCellera Biologics Enters into Research Agreement with Pfizer 199

Pfizer Partners with NovaMedica 200

PegBio Partners with Pfizer 201

Pfizer Enters into Agreement with National Cancer Institute 202

Debiopharm Partners with Merck and Pfizer 203

Transgene Enters into Agreement with Merck and Pfizer 204

Circle Pharma Partners with Pfizer 205

Pfizer and CR Saike Pharma Enter into Distribution Agreement 206

Pfizer Partners with inVentiv Health 207

Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 208

BioRap Technologies Enters into Co- Development Agreement with Pfizer 209

Pfizer Enters into Agreement with NovaQuest Capital Management 210

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 211

Merck, Pfizer and Verastem Enter into Agreement 212

Pfizer Enters into Partnership Agreement with RPI Finance Trust 213

Pfizer Enters into Agreement with California Institute for Biomedical Research 214

Pfizer Enters into Research Agreement with Adaptive Biotech 215

Merck, Pfizer and Syndax Pharma Enter into Agreement 216

Heptares Therapeutics Enters into Agreement with Pfizer 217

Pfizer Enters into Agreement with Biovac Institute 218

Pfizer Enters into Agreement with GlaxoSmithKline 219

Pfizer Enters into Agreement with Synthon 220

Centers for Therapeutic Innovation Enters into Research Agreement with Jeffrey Modell Foundation 221

CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 222

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 223

Regimmune Enters into Research Agreement with JDRF and Pfizer 224

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 225

HiFiBiO Enters into Research Agreement with Pfizer 226

Pharmacosmos Enters into Agreement with Pfizer 227

Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 228

University of Dundee Enters into Research Agreement with Pfizer 229

HemoShear Enters into Agreement with Pfizer 230

Pfizer Enters into Co-Development Agreement with Merck 231

Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 233

Crohns & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 234

Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 235

X-Chem Enters into Co-Development Agreement with Pfizer 237

KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 238

Cambridge University, Imperial College London, Kings College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 239

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 241

BioRestorative Therapies Enters into Research Agreement with Pfizer 242

Process Systems Enters Into Co-Development Agreement With Pfizer 243

Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 244

Octapharma Enters Into Co-Marketing Agreement With Pfizer 245

Protagen Enters Into Biomarker Discovery Agreement With Pfizer 246

Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 247

Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 248

Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 249

Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 250

Centers For Therapeutic Innovation Partners with UC San Francisco 251

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 252

Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 253

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 254

OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 255

Humedica Enters Into Agreement With Pfizer 257

AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 258

Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 259

Apredica Enters Into Research Agreement With Pfizer 260

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Pfizer Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, immune disorders and rare diseases, besides vaccines. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells prescription medicines through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It sells consumer healthcare products through pharmacies, retail chains, distributors and grocery and convenience stores. The company provides its products in the North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

Pfizer Inc (PFE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 13

List of Figures 19

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25

Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26

Pfizer Inc, Pharmaceuticals & Healthcare, Deal Details 50

Asset Purchase 50

Pfizer to Acquire Neksium Brand from AstraZeneca 50

Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 51

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 53

Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 54

Medivation Acquires Rights to Talazoparib from BioMarin Pharma 55

Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 56

Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 57

Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 58

Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 60

Pfizer Acquires Melanocortin Receptors from MRC Technology 62

Pfizer Plans To Sell Certain Ohthalmology R&D Assets 63

Pfizer Completes Acquisition Of Polocard From Polpharma For USD 32 Million 64

Venture Financing 65

Morphic Therapeutic Raises USD80 Million in Series B Financing 65

Biodesy Raises USD20 Million in Series C Venture Financing 67

4D Molecular Therapeutics Raises USD90 Million in Series B Venture Financing 68

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 70

Therachon Raises USD60 Million in Mezzanine Financing 72

Nimbus Therapeutics Raises USD65 Million in Financing 74

Cortexyme Raises USD76 Million in Series B Venture Financing 76

Strata Oncology Raises USD26 Million in Series B Venture Financing 78

Allogene Therapeutics to Raise USD300 Million in Series A Financing 80

Adapsyn Bioscience Raises Funds through Venture Financing 82

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 83

Cydan Raises USD34 Million in Venture Financing 85

Palleon Pharma Raises USD47.6 Million in Series A Financing 86

SpringWorks Therapeutics Raises USD103 Million in Series A Financing 87

Complexa Raises USD62 Million in Series C Financing 89

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 90

Neuronetics Raises USD15 Million in Series G Round of Financing 92

Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 94

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 96

Circle Pharma Raises Funds through Series A Preferred Stock Financing 98

Ixchelsis Raises Additional USD12 Million in Venture Financing 99

Vtesse Raises USD17 Million in Extended Series A Financing 100

Second Genome Raises USD8.4 Million in Extended Series B Financing 101

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 102

Storm Therapeutics Raises USD16 Million in Series A Venture Financing 104

Blade Therapeutics Raises USD27 Million in Series B Financing 105

Second Genome Raises USD42.6 Million in Series B Financing 107

Cydan Development Raises USD31 Million in Series A Financing 109

Metabomed Raises USD18 Million in Series A Venture Financing 110

Mission Therapeutics Raises USD85.7 Million in Financing Round 111

Biodesy Raises USD10 Million in Series B Financing 112

Lodo Therapeutics Raises USD17 Million in Series A Financing 113

Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 115

NextCure Raises USD67 Million in Series A Financing 116

Petra Pharma Raises USD48 Million in Series A Financing 118

Cortexyme Raises USD15 Million in Series A Financing Round 120

Merus Raises USD46.4 Million in First Tranche of Series C Financing 121

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 123

Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 125

Mirna Therapeutics Raises USD41.8 Million in Series D Financing 126

Nimbus Therapeutics Raises USD43 Million in Series B Financing 128

Mersana Therapeutics Raises USD35 Million in Series B Financing 130

Vtesse Raises USD25 Million in Series A Financing 131

CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 132

Ziarco Raises USD33 Million in Series B Venture Financing 133

Quartet Medicine Raises USD17 Million in Series A Venture Financing 134

Circle Pharma Raises Funds through Seed Financing 135

Epic Sciences Raises USD30 Million in Series C Venture Financing 136

NexImmune Raises USD3 Million in Venture Financing 137

Mission Therapeutics Raises USD 32 Million In Series B Financing 138

Biodesy Raises USD 15 Million In Series A Financing 139

Merus Raises USD 42 Million In Extended Series B Financing 140

Cydan Raises USD 26 Million In Venture Financing 142

Esperion Therapeutics Raises USD 33 Million In Venture Financing 144

Aquinox Pharma Raises USD 18 Million In Series C Financing 146

Esperion Therapeutics Raises USD 1 Million In Venture Financing 147

Flexion Therapeutics Raises USD20 Million In Series B Financing 148

Rhythm Pharma Raises USD 33 Million In Series B Financing 149

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 151

Epic Sciences Raises USD 13 Million In Series B Financing 153

Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 154

Mirna Therapeutics Raises USD 34 Million In Series C Financing 155

Mersana Therapeutics Raises USD 27 Million In Series A-1 Financing 157

InnoPharma Raises USD 8 Million In Venture Financing 159

Flexion Therapeutics Raises Additional USD 13 Million In Series A Financing 160

Celladon Raises Additional USD 10 Million In Series D Financing 161

Private Equity 163

Bain Capital May Acquire Laboratorio Teuto Brasileiro 163

Partnerships 164

Pfizer Enters into Licensing Agreement with Scripps Research Institute 164

Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 165

Nektar Therapeutics Enters into Collaboration Agreement with Pfizer 166

Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 167

Pfizer Enters into Co-Development Agreement with Novartis 168

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 169

Bain Capital and Pfizer Form Joint Venture 170

Myriad Genetics and Pfizer Enter into Agreement 171

Calithera Biosciences Enters into Partnership with Pfizer 172

Atomwise Enters into Evaluation Agreement with Pfizer 173

CYTOO Enters into Research and Option Agreement with Pfizer 174

Checkmate Pharma Enters into Partnership with Merck and Pfizer 175

BioNTech Enters into R&D Agreement with Pfizer 176

Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 177

Vyriad Enters into Collaboration Agreement with Merck and Pfizer 178

XtalPi Enters into Research Agreement with Pfizer 179

BioDuro Enters into Agreement with Pfizer 180

Neofluidics Enters into Agreement with Pfizer 181

NetVation DL Medicine Enters into Research Agreement with Pfizer 182

MindImmune Therapeutics Enters into Research Agreement with Pfizer 183

Kite Pharma Enters into Partnership with Pfizer 184

Adapsyn Bioscience Enters into Research Agreement with Pfizer 185

Array BioPharma Enters into Agreement with Pfizer 186

Encycle Therapeutics Enters into Research Agreement with Pfizer 187

Themis Medicare Forms Joint Venture Agreement with Global Pharmatech 188

University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 189

Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 190

Alcyone Lifesciences Enters into Agreement with Pfizer 191

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 192

Astellas Pharma Amends Agreement with Pfizer 193

EpiThany Enters into Agreement with Merck and Pfizer 194

VAXIMM Enters into Agreement with Merck and Pfizer 195

Domain Therapeutics Enters into Partnership with Pfizer 196

Pfizer Enters into Agreement with Washington University in St. Louis 197

Edelris Enters into Research Agreement with Pfizer 198

AbCellera Biologics Enters into Research Agreement with Pfizer 199

Pfizer Partners with NovaMedica 200

PegBio Partners with Pfizer 201

Pfizer Enters into Agreement with National Cancer Institute 202

Debiopharm Partners with Merck and Pfizer 203

Transgene Enters into Agreement with Merck and Pfizer 204

Circle Pharma Partners with Pfizer 205

Pfizer and CR Saike Pharma Enter into Distribution Agreement 206

Pfizer Partners with inVentiv Health 207

Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 208

BioRap Technologies Enters into Co- Development Agreement with Pfizer 209

Pfizer Enters into Agreement with NovaQuest Capital Management 210

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 211

Merck, Pfizer and Verastem Enter into Agreement 212

Pfizer Enters into Partnership Agreement with RPI Finance Trust 213

Pfizer Enters into Agreement with California Institute for Biomedical Research 214

Pfizer Enters into Research Agreement with Adaptive Biotech 215

Merck, Pfizer and Syndax Pharma Enter into Agreement 216

Heptares Therapeutics Enters into Agreement with Pfizer 217

Pfizer Enters into Agreement with Biovac Institute 218

Pfizer Enters into Agreement with GlaxoSmithKline 219

Pfizer Enters into Agreement with Synthon 220

Centers for Therapeutic Innovation Enters into Research Agreement with Jeffrey Modell Foundation 221

CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 222

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 223

Regimmune Enters into Research Agreement with JDRF and Pfizer 224

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 225

HiFiBiO Enters into Research Agreement with Pfizer 226

Pharmacosmos Enters into Agreement with Pfizer 227

Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 228

University of Dundee Enters into Research Agreement with Pfizer 229

HemoShear Enters into Agreement with Pfizer 230

Pfizer Enters into Co-Development Agreement with Merck 231

Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 233

Crohns & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 234

Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 235

X-Chem Enters into Co-Development Agreement with Pfizer 237

KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 238

Cambridge University, Imperial College London, Kings College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 239

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 241

BioRestorative Therapies Enters into Research Agreement with Pfizer 242

Process Systems Enters Into Co-Development Agreement With Pfizer 243

Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 244

Octapharma Enters Into Co-Marketing Agreement With Pfizer 245

Protagen Enters Into Biomarker Discovery Agreement With Pfizer 246

Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 247

Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 248

Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 249

Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 250

Centers For Therapeutic Innovation Partners with UC San Francisco 251

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 252

Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 253

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 254

OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 255

Humedica Enters Into Agreement With Pfizer 257

AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 258

Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 259

Apredica Enters Into Research Agreement With Pfizer 260

Mochida Pharma Enters Into Agreement With Hospira Japan To Distribute And Promote Oncology Products 261

Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 262

Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 263

SFJ Pharma Enters Into Co-Development Agreement With Pfizer For Dacomitinib 264

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 265

Nodality Enters Into Agreement With Pfizer For Single Cell Network Profiling Technology 266

Pfizer Enters Into Co-Development Agreement With Harvard University 267

Cold Spring Harbor Labs Enters Into Research Agreement With Pfizer For New Cancer Therapies 268

Ildong Pharma Enters Into Co-Promotion Agreement With Pfizer Pharma For Generic Drugs 269

Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 270

Pfizer Enters into Co-Promotion Agreement with Specpharm 271

Pfizer Plans To Enter Into Co-Development Agreement With India-Based Pharma Company 272

Pfizer Enters Into Co-Marketing Agreement With Biologics For Inlyta 273

KineMed Extends Research Agreement With Pfizer 274

ICM Enters into Research Collaboration with Pfizer 275

KineMed Enters Into Co-Development Agreement With Pfizer 276

SFJ Pharma Enters Into Co-Development Agreement With Pfizer 277

Licensing Agreements 278

Pfizer Enters into Licensing Agreement with Cancer Therapeutics CRC 278

Pfizer Amends Licensing Agreement with Spark Therapeutics 279

Allogene Therapeutics Enters into Licensing Agreement with Pfizer 281

Suzhou Kintor Pharma Enters into Licensing Agreement with Pfizer 282

Imcyse Research Agreement with Pfizer 283

Pfizer Enters into Licensing Agreement with Distributed Bio for SuperHuman Platform 284

Pfizer Enters into Licensing Agreement with Berkeley Lights 285

Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 286

Pfizer Enters into Licensing Agreement with Arvinas 287

SpringWorks Therapeutics Receives Rights from Pfizer 288

Pfizer Amends Licensing Agreement with Basilea Pharma 289

Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 290

Pfizer Enters into Licensing Agreement with HitGen 291

Absorption Systems Enters into Licensing Agreement with Pfizer 292

Pfizer Enters into Licensing Agreement with BioInvent International 293

Pfizer Enters into Licensing Agreement with Ab Initio Biotherapeutics 294

Pfizer Enters into Licensing Agreement with OncoImmune 295

Pfizer Enters into Option Agreement with AnTolRx 296

Pfizer Enters into Licensing Agreement with Western Oncolytics 297

Shire Enters into Licensing Agreement with Pfizer 298

Pfizer Inc - Key Competitors 499

Pfizer Inc - Key Employees 500

Pfizer Inc - Locations And Subsidiaries 502

Head Office 502

Other Locations & Subsidiaries 502

Joint Venture 525

Recent Developments 526

Strategy And Business Planning 526

Oct 30, 2018: Novartis and Pfizer partner to advance NASH therapy 526

Oct 24, 2018: Pfizer partners with Bain Capital to launch new CNS therapy firm 527

Jul 24, 2018: Pfizer to build $465m injectable medicines facility in US 528

Jul 11, 2018: Pfizer to split into three businesses 529

Jan 04, 2018: Jacobs Appointed as EPCM Contractor for New Gene Therapy Manufacturing Facility 530

Oct 10, 2017: Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business 531

Aug 07, 2017: Pfizer to Invest in Gene Therapy Manufacturing Facility in North Carolina 532

Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 534

Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri 535

Mar 06, 2017: Pfizer Selects Turner & Townsend For Expansion Of Its Clinical Research Unit In Belgium 536

Financial Announcements 537

Jul 31, 2018: Pfizer reports second-quarter 2018 results 537

May 01, 2018: Pfizer Reports First-Quarter 2018 Results 542

Jan 30, 2018: Pfizer Reports Fourth-Quarter And Full-Year 2017 Results 546

Oct 31, 2017: Pfizer Reports Third-Quarter 2017 Results 553

Oct 30, 2017: Pfizer reports thirdquarter 2018 results 556

Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results 565

May 02, 2017: Pfizer Reports First-Quarter 2017 Results 569

Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results 573

Corporate Communications 578

Oct 09, 2018: Pfizer announces Executive Leadership Team 578

Oct 01, 2018: Pfizer announces CEO succession 579

Sep 18, 2018: Good Health and Well-Being : A Mission for Business and Society 581

Jun 12, 2018: Extending Antibiotic Donations to Eliminate Trachoma 582

Mar 05, 2018: Pfizer Names Dan R. Littman As Board Director 583

Feb 23, 2018: Pfizer Appoints Albert Bourla As Board Director 584

Jan 08, 2018: Pfizer Ends Alzheimer's and Parkinson's Disease Programs, to Eliminate 300 Jobs 585

Nov 13, 2017: Pfizer Names Albert Bourla Chief Operating Officer 586

Oct 04, 2017: AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics Join Walgreens to Combat Prescription Drug Abuse by Expanding Safe Medication Disposal Program 588

Feb 23, 2017: Ronald E. Blaylock Elected to Pfizers Board of Directors 590

Legal and Regulatory 591

Jun 11, 2018: Pfizer wins appeal against CMA fine over epilepsy drug price 591

May 24, 2018: Drug Maker Pfizer Agrees to Pay $23.85 Million to Resolve False Claims Act Liability for Paying Kickbacks 592

Government and Public Interest 594

Oct 04, 2018: Pfizer to award more than 3 million in grants to further breast cancer research 594

Sep 04, 2018: Pfizer estimates $100M in supply chain costs for adapting to Brexit requirements 595

Jul 11, 2018: Pfizer reverses drug price hike after President Trumps protests 596

Jun 08, 2018: GEA supports Pfizer to change from batch-based to continuous manufacturing 597

May 30, 2018: The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families 598

Feb 02, 2018: BCRF Announces Expansion of the Drug Research Collaborative 599

Nov 20, 2017: NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care 600

Nov 16, 2017: Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance 601


List Of Figure

List of Figures

Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25


List Of Table

List of Tables

Pfizer Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

Pfizer Inc, Deals By Therapy Area, 2012 to YTD 2018 23

Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25

Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26

Pfizer to Acquire Neksium Brand from AstraZeneca 50

Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 51

Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 53

Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 54

Medivation Acquires Rights to Talazoparib from BioMarin Pharma 55

Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 56

Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 57

Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 58

Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 60

Pfizer Acquires Melanocortin Receptors from MRC Technology 62

Pfizer Plans To Sell Certain Ohthalmology R&D Assets 63

Pfizer Completes Acquisition Of Polocard From Polpharma For USD 32 Million 64

Morphic Therapeutic Raises USD80 Million in Series B Financing 65

Biodesy Raises USD20 Million in Series C Venture Financing 67

4D Molecular Therapeutics Raises USD90 Million in Series B Venture Financing 68

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 70

Therachon Raises USD60 Million in Mezzanine Financing 72

Nimbus Therapeutics Raises USD65 Million in Financing 74

Cortexyme Raises USD76 Million in Series B Venture Financing 76

Strata Oncology Raises USD26 Million in Series B Venture Financing 78

Allogene Therapeutics to Raise USD300 Million in Series A Financing 80

Adapsyn Bioscience Raises Funds through Venture Financing 82

Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 83

Cydan Raises USD34 Million in Venture Financing 85

Palleon Pharma Raises USD47.6 Million in Series A Financing 86

SpringWorks Therapeutics Raises USD103 Million in Series A Financing 87

Complexa Raises USD62 Million in Series C Financing 89

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 90

Neuronetics Raises USD15 Million in Series G Round of Financing 92

Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 94

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 96

Circle Pharma Raises Funds through Series A Preferred Stock Financing 98

Ixchelsis Raises Additional USD12 Million in Venture Financing 99

Vtesse Raises USD17 Million in Extended Series A Financing 100

Second Genome Raises USD8.4 Million in Extended Series B Financing 101

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 102

Storm Therapeutics Raises USD16 Million in Series A Venture Financing 104

Blade Therapeutics Raises USD27 Million in Series B Financing 105

Second Genome Raises USD42.6 Million in Series B Financing 107

Cydan Development Raises USD31 Million in Series A Financing 109

Metabomed Raises USD18 Million in Series A Venture Financing 110

Mission Therapeutics Raises USD85.7 Million in Financing Round 111

Biodesy Raises USD10 Million in Series B Financing 112

Lodo Therapeutics Raises USD17 Million in Series A Financing 113

Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 115

NextCure Raises USD67 Million in Series A Financing 116

Petra Pharma Raises USD48 Million in Series A Financing 118

Cortexyme Raises USD15 Million in Series A Financing Round 120

Merus Raises USD46.4 Million in First Tranche of Series C Financing 121

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 123

Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 125

Mirna Therapeutics Raises USD41.8 Million in Series D Financing 126

Nimbus Therapeutics Raises USD43 Million in Series B Financing 128

Mersana Therapeutics Raises USD35 Million in Series B Financing 130

Vtesse Raises USD25 Million in Series A Financing 131

CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 132

Ziarco Raises USD33 Million in Series B Venture Financing 133

Quartet Medicine Raises USD17 Million in Series A Venture Financing 134

Circle Pharma Raises Funds through Seed Financing 135

Epic Sciences Raises USD30 Million in Series C Venture Financing 136

NexImmune Raises USD3 Million in Venture Financing 137

Mission Therapeutics Raises USD 32 Million In Series B Financing 138

Biodesy Raises USD 15 Million In Series A Financing 139

Merus Raises USD 42 Million In Extended Series B Financing 140

Cydan Raises USD 26 Million In Venture Financing 142

Esperion Therapeutics Raises USD 33 Million In Venture Financing 144

Aquinox Pharma Raises USD 18 Million In Series C Financing 146

Esperion Therapeutics Raises USD 1 Million In Venture Financing 147

Flexion Therapeutics Raises USD20 Million In Series B Financing 148

Rhythm Pharma Raises USD 33 Million In Series B Financing 149

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 151

Epic Sciences Raises USD 13 Million In Series B Financing 153

Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 154

Mirna Therapeutics Raises USD 34 Million In Series C Financing 155

Mersana Therapeutics Raises USD 27 Million In Series A-1 Financing 157

InnoPharma Raises USD 8 Million In Venture Financing 159

Flexion Therapeutics Raises Additional USD 13 Million In Series A Financing 160

Celladon Raises Additional USD 10 Million In Series D Financing 161

Bain Capital May Acquire Laboratorio Teuto Brasileiro 163

Pfizer Enters into Licensing Agreement with Scripps Research Institute 164

Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 165

Nektar Therapeutics Enters into Collaboration Agreement with Pfizer 166

Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 167

Pfizer Enters into Co-Development Agreement with Novartis 168

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 169

Bain Capital and Pfizer Form Joint Venture 170

Myriad Genetics and Pfizer Enter into Agreement 171

Calithera Biosciences Enters into Partnership with Pfizer 172

Atomwise Enters into Evaluation Agreement with Pfizer 173

CYTOO Enters into Research and Option Agreement with Pfizer 174

Checkmate Pharma Enters into Partnership with Merck and Pfizer 175

BioNTech Enters into R&D Agreement with Pfizer 176

Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 177

Vyriad Enters into Collaboration Agreement with Merck and Pfizer 178

XtalPi Enters into Research Agreement with Pfizer 179

BioDuro Enters into Agreement with Pfizer 180

Neofluidics Enters into Agreement with Pfizer 181

NetVation DL Medicine Enters into Research Agreement with Pfizer 182

MindImmune Therapeutics Enters into Research Agreement with Pfizer 183

Kite Pharma Enters into Partnership with Pfizer 184

Adapsyn Bioscience Enters into Research Agreement with Pfizer 185

Array BioPharma Enters into Agreement with Pfizer 186

Encycle Therapeutics Enters into Research Agreement with Pfizer 187

Themis Medicare Forms Joint Venture Agreement with Global Pharmatech 188

University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 189

Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 190

Alcyone Lifesciences Enters into Agreement with Pfizer 191

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 192

Astellas Pharma Amends Agreement with Pfizer 193

EpiThany Enters into Agreement with Merck and Pfizer 194

VAXIMM Enters into Agreement with Merck and Pfizer 195

Domain Therapeutics Enters into Partnership with Pfizer 196

Pfizer Enters into Agreement with Washington University in St. Louis 197

Edelris Enters into Research Agreement with Pfizer 198

AbCellera Biologics Enters into Research Agreement with Pfizer 199

Pfizer Partners with NovaMedica 200

PegBio Partners with Pfizer 201

Pfizer Enters into Agreement with National Cancer Institute 202

Debiopharm Partners with Merck and Pfizer 203

Transgene Enters into Agreement with Merck and Pfizer 204

Circle Pharma Partners with Pfizer 205

Pfizer and CR Saike Pharma Enter into Distribution Agreement 206

Pfizer Partners with inVentiv Health 207

Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 208

BioRap Technologies Enters into Co- Development Agreement with Pfizer 209

Pfizer Enters into Agreement with NovaQuest Capital Management 210

Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 211

Merck, Pfizer and Verastem Enter into Agreement 212

Pfizer Enters into Partnership Agreement with RPI Finance Trust 213

Pfizer Enters into Agreement with California Institute for Biomedical Research 214

Pfizer Enters into Research Agreement with Adaptive Biotech 215

Merck, Pfizer and Syndax Pharma Enter into Agreement 216

Heptares Therapeutics Enters into Agreement with Pfizer 217

Pfizer Enters into Agreement with Biovac Institute 218

Pfizer Enters into Agreement with GlaxoSmithKline 219

Pfizer Enters into Agreement with Synthon 220

Centers for Therapeutic Innovation Enters into Research Agreement with Jeffrey Modell Foundation 221

CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 222

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 223

Regimmune Enters into Research Agreement with JDRF and Pfizer 224

BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 225

HiFiBiO Enters into Research Agreement with Pfizer 226

Pharmacosmos Enters into Agreement with Pfizer 227

Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 228

University of Dundee Enters into Research Agreement with Pfizer 229

HemoShear Enters into Agreement with Pfizer 230

Pfizer Enters into Co-Development Agreement with Merck 231

Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 233

Crohns & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 234

Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 235

X-Chem Enters into Co-Development Agreement with Pfizer 237

KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 238

Cambridge University, Imperial College London, Kings College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 239

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 241

BioRestorative Therapies Enters into Research Agreement with Pfizer 242

Process Systems Enters Into Co-Development Agreement With Pfizer 243

Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 244

Octapharma Enters Into Co-Marketing Agreement With Pfizer 245

Protagen Enters Into Biomarker Discovery Agreement With Pfizer 246

Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 247

Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 248

Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 249

Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 250

Centers For Therapeutic Innovation Partners with UC San Francisco 251

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 252

Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 253

Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 254

OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 255

Humedica Enters Into Agreement With Pfizer 257

AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 258

Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 259

Apredica Enters Into Research Agreement With Pfizer 260

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Pfizer Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.